Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

Overview
Date Founded

2014

Headquarters

9390 Towne Centre Drive,Suite 200,San Diego, CA 92121

Type of Company

Public

Employees (Worldwide)

206

Industries

Biotechnology
Pharmaceuticals

Company Description

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.

Contact Data
Trying to get in touch with decision makers at Poseida Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer & Founder

President & Chief Business Officer

Chief Operating Officer

General Counsel, Chief Compliance Officer & Corporate Secretary

Chief Medical Officer

Chief Human Resources Officer

Senior Vice President, Research & Development

Senior Vice President, Finance

Vice President, Corporate Affairs

Vice President, Intellectual Property

Paths to Poseida Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Poseida Therapeutics, Inc.
Owners & Shareholders
Details Hidden

PCM seeks to provide clients with consistently superior risk-adjusted rates of return through implementing event-driven strategies. Their investment strategies generally focus on an event or a catalyst that will move an equity price, an equity spread, a credit spread, or an implied volatility spread. Their investment strategies may include: merger arbitrage, catalyst-driven credit investing, special situation investing and distressed investing. Catalyst events may include mergers, acquisitions, spin-offs, carve-outs, tender offers, split-off exchange offers, share class spreads, re-organizations and corporate distress. PCM seeks to trade in all forms of the capital structure of companies involved in catalysts and events and to create the best risk/reward trade possible within the corporate capital structure. They attempt to limit risk through diversification and hedging. The firm may choose to take control positions in an attempt to create their own catalyst or event. In managing the fund’s portfolio, PCM relies on fundamental analysis supplemented by quantitative analytics and portfolio management techniques. They take both long and short positions for their clients in a broad range of public and private debt securities, equity securities, options, derivatives and credit derivatives (including credit default swaps), trade claims, bank debt participations and other instruments. PCM invests within and outside of the US, as well as in issuers in various stages of financial distress.

Details Hidden

Aisling Capital takes an active approach to investing and pursues a multi-strategy investment approach. The firm makes investment decisions driven by fundamental assessment of scientific, regulatory, financial and commercial risks. They invest across the life sciences, including seed and venture financings of development-stage companies, small-cap publicly traded equities, structured debt and royalty deals and large-cap leveraged buyouts of profitable companies.

Details Hidden

PCM seeks to provide clients with consistently superior risk-adjusted rates of return through implementing event-driven strategies. Their investment strategies generally focus on an event or a catalyst that will move an equity price, an equity spread, a credit spread, or an implied volatility spread. Their investment strategies may include: merger arbitrage, catalyst-driven credit investing, special situation investing and distressed investing. Catalyst events may include mergers, acquisitions, spin-offs, carve-outs, tender offers, split-off exchange offers, share class spreads, re-organizations and corporate distress. PCM seeks to trade in all forms of the capital structure of companies involved in catalysts and events and to create the best risk/reward trade possible within the corporate capital structure. They attempt to limit risk through diversification and hedging. The firm may choose to take control positions in an attempt to create their own catalyst or event. In managing the fund’s portfolio, PCM relies on fundamental analysis supplemented by quantitative analytics and portfolio management techniques. They take both long and short positions for their clients in a broad range of public and private debt securities, equity securities, options, derivatives and credit derivatives (including credit default swaps), trade claims, bank debt participations and other instruments. PCM invests within and outside of the US, as well as in issuers in various stages of financial distress.

Recent Transactions
Details Hidden

Poseida Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Poseida Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Poseida Therapeutics, Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Details Hidden
Advisors & Consultants
Publicist

Managing Director at Canale Communications, Inc.

Key Stats and Financials As of 2020
Market Capitalization
$617M
Total Enterprise Value
$145M
Earnings Per Share
$-3.61
Revenue
$0
Net Profit
$-130M
EBITDA
$-146M
Total Debt
$59.3M
Total Equity
$262M
TEVNet Income
-1.12x
Debt TEV
0.41x
Three Year Compounded Annual Growth Rate Of Revenue
-100%
Investors
Details Hidden

PCM seeks to provide clients with consistently superior risk-adjusted rates of return through implementing event-driven strategies. Their investment strategies generally focus on an event or a catalyst that will move an equity price, an equity spread, a credit spread, or an implied volatility spread. Their investment strategies may include: merger arbitrage, catalyst-driven credit investing, special situation investing and distressed investing. Catalyst events may include mergers, acquisitions, spin-offs, carve-outs, tender offers, split-off exchange offers, share class spreads, re-organizations and corporate distress. PCM seeks to trade in all forms of the capital structure of companies involved in catalysts and events and to create the best risk/reward trade possible within the corporate capital structure. They attempt to limit risk through diversification and hedging. The firm may choose to take control positions in an attempt to create their own catalyst or event. In managing the fund’s portfolio, PCM relies on fundamental analysis supplemented by quantitative analytics and portfolio management techniques. They take both long and short positions for their clients in a broad range of public and private debt securities, equity securities, options, derivatives and credit derivatives (including credit default swaps), trade claims, bank debt participations and other instruments. PCM invests within and outside of the US, as well as in issuers in various stages of financial distress.

Details Hidden

Chief Executive Officer & Founder at Poseida Therapeutics, Inc.

Details Hidden

Vivo Capital is an active manager which invests in companies located in the US. The firm participates in early stage capital transactions and focuses on sectors such as healthcare and life sciences.

Suppliers
Johnson & Johnson Biotechnology | New Brunswick, New Jersey

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government. Johnson & Johnson is headquartered in New Brunswick, New Jersey, the consumer division being located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in 60 countries and products sold in over 175 countries. Johnson & Johnson had worldwide sales of $82.6 billion during calendar year 2020. Johnson & Johnson's brands include numerous household names of medications and first aid supplies. Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson's Baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact lenses. Johnson & Johnson's pharmaceutical arm is Janssen Pharmaceutica.

Genus Oncology LLC Hospitals & Patient Services | Chicago, Illinois

Genus Oncology LLC operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing first-in-class agents against the MUC1-C oncoprotein for the treatment of patients with refractory cancers. The company was founded in 2007 and is headquartered in Chicago, IL.

TeneoBio, Inc. Biotechnology | Newark, CA

TeneoBio, Inc. operates as a biotechnology company that develops biologics, human heavy chain antibodies, as therapeutics against cancer, autoimmunity, and infectious diseases. Its products provides treatment of multiple myeloma, prostate cancer, immune disorders, and AIDS. The company was founded by Roland Buelow, on August 9, 2009 and is headquartered in Menlo Park, CA.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government. Johnson & Johnson is headquartered in New Brunswick, New Jersey, the consumer division being located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in 60 countries and products sold in over 175 countries. Johnson & Johnson had worldwide sales of $82.6 billion during calendar year 2020. Johnson & Johnson's brands include numerous household names of medications and first aid supplies. Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson's Baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact lenses. Johnson & Johnson's pharmaceutical arm is Janssen Pharmaceutica.

Alnylam Pharmaceuticals, Inc. Pharmaceuticals - Cambridge, Massachusetts

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

AstraZeneca Plc Pharmaceuticals - Cambridge, United Kingdom

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Poseida Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Poseida Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Poseida Therapeutics, Inc..